Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 278

1.

Re: Association of Black Race with Prostate Cancer-specific and Other-cause Mortality Dess RT, Hartman HE, Mahal BA, et al JAMA Oncol 2019;5:975-83.

Tan WP, Polascik TJ.

Eur Urol. 2019 Oct 17. pii: S0302-2838(19)30686-4. doi: 10.1016/j.eururo.2019.08.036. [Epub ahead of print] No abstract available.

PMID:
31630893
2.

Considerations of germline testing in prostate cancer screening.

Polascik TJ, Orabi H.

Can J Urol. 2019 Oct;26(5S2):46-47.

PMID:
31629431
3.

Racial Discrepancies in Overall Survival among Men Treated with Radium-223.

Zhao H, Howard L, De Hoedt A, Terris MK, Amling C, Kane C, Cooperberg M, Aronson W, Klaassen Z, Polascik TJ, Vidal AC, Freedland S.

J Urol. 2019 Sep 3:101097JU0000000000000524. doi: 10.1097/JU.0000000000000524. [Epub ahead of print]

PMID:
31479407
4.

Editorial Comment.

Polascik TJ.

J Urol. 2019 Aug 30:10109701JU0000581800016515c. doi: 10.1097/01.JU.0000581800.01651.5c. [Epub ahead of print] No abstract available.

PMID:
31469606
5.

Diagnosis and Management of Local Recurrence After Prostate Focal Therapy: Challenges and Solutions.

Aminsharifi A, Polascik TJ.

Eur Urol Oncol. 2019 Sep;2(5):539-540. doi: 10.1016/j.euo.2019.07.008. Epub 2019 Aug 4. No abstract available.

PMID:
31387794
6.

Reply by Authors.

Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC.

J Urol. 2019 Jul 31:10109701JU00005793126115939. doi: 10.1097/01.JU.0000579312.61159.39. [Epub ahead of print] No abstract available.

PMID:
31364932
7.

Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?

Tay KJ, Polascik TJ, Howard LE, Salama JK, Schulman AA, Chen Z, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.

Clin Genitourin Cancer. 2019 Oct;17(5):e930-e938. doi: 10.1016/j.clgc.2019.05.007. Epub 2019 May 24.

PMID:
31257075
8.

Salvage Prostate Cryoablation for the Management of Local Recurrence After Primary Cryotherapy: A Retrospective Analysis of Functional and Intermediate-Term Oncological Outcomes Associated With a Second Therapeutic Freeze.

Aminsharifi A, Jibara G, Tsivian E, Tsivian M, Elshafei A, Polascik TJ.

Clin Genitourin Cancer. 2019 Aug;17(4):e831-e836. doi: 10.1016/j.clgc.2019.05.014. Epub 2019 May 28.

PMID:
31213413
9.

SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer.

Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC.

J Urol. 2019 May 30:101097JU0000000000000357. doi: 10.1097/JU.0000000000000357. [Epub ahead of print]

PMID:
31144591
10.

Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy.

Aminsharifi A, Schulman A, Howard LE, Tay KJ, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ.

Cancer. 2019 Sep 1;125(17):3025-3032. doi: 10.1002/cncr.32168. Epub 2019 May 1.

PMID:
31042315
11.

The use of multiparametric MRI in diagnosis and active surveillance of prostate cancer.

Polascik TJ.

Clin Adv Hematol Oncol. 2018 Dec;16(12):798-799. No abstract available.

PMID:
30843887
12.

Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.

Aminsharifi A, Simon R, Polascik TJ, Robertson CN, Sudan DL, Collins BH, Moul JW.

J Urol. 2019 Sep;202(3):469-474. doi: 10.1097/JU.0000000000000207. Epub 2019 Aug 8. Review.

PMID:
30835631
13.

Clinicopathological characteristics of surgically treated localized renal masses in patients previously exposed to chemotherapy.

Tsivian E, Tsivian M, Sze C, Schulman A, Polascik TJ.

Int Braz J Urol. 2019 Mar-Apr;45(2):332-339. doi: 10.1590/S1677-5538.IBJU.2018.0126.

14.

Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project.

van Luijtelaar A, Greenwood BM, Ahmed HU, Barqawi AB, Barret E, Bomers JGR, Brausi MA, Choyke PL, Cooperberg MR, Eggener S, Feller JF, Frauscher F, George AK, Hindley RG, Jenniskens SFM, Klotz L, Kovacs G, Lindner U, Loeb S, Margolis DJ, Marks LS, May S, Mcclure TD, Montironi R, Nour SG, Oto A, Polascik TJ, Rastinehad AR, De Reyke TM, Reijnen JS, de la Rosette JJMCH, Sedelaar JPM, Sperling DS, Walser EM, Ward JF, Villers A, Ghai S, F├╝tterer JJ.

World J Urol. 2019 Oct;37(10):2147-2153. doi: 10.1007/s00345-019-02636-7. Epub 2019 Jan 22.

15.
16.

Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.

Aminsharifi A, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Polascik TJ, Freedland SJ.

Clin Genitourin Cancer. 2019 Feb;17(1):e140-e149. doi: 10.1016/j.clgc.2018.09.020. Epub 2018 Oct 4.

PMID:
30366879
17.

Focal therapy of prostate and kidney cancer.

Aminsharifi A, de la Rosette J, Polascik TJ.

Curr Opin Urol. 2018 Nov;28(6):491-492. doi: 10.1097/MOU.0000000000000552. No abstract available.

PMID:
30239417
18.

Three-dimensional localization and targeting of prostate cancer foci with imaging and histopathologic correlation: establishing a multidisciplinary team for quality improvement.

Aminsharifi A, Gupta RT, Huang J, Polascik TJ.

Curr Opin Urol. 2018 Nov;28(6):506-511. doi: 10.1097/MOU.0000000000000554. Review.

PMID:
30239416
19.

Primary care perspective and implementation of a multidisciplinary, institutional prostate cancer screening algorithm embedded in the electronic health record.

Aminsharifi A, Schulman A, Anderson J, Fish L, Oeffinger K, Shah K, Sze C, Tay KJ, Tsivian E, Polascik TJ.

Urol Oncol. 2018 Nov;36(11):502.e1-502.e6. doi: 10.1016/j.urolonc.2018.07.016. Epub 2018 Aug 28.

PMID:
30170982
20.

Does Any Racial Disparity Exist in Oncologic Outcomes After Primary Cryotherapy for Prostate Cancer? A Matched-pair Comparative Analysis of the Cryo On-Line Data Registry.

Aminsharifi A, Polascik TJ, Tsivian M, Schulman A, Tsivian E, Tay KJ, Elshafei A, Jones JS.

Clin Genitourin Cancer. 2018 Oct;16(5):e1073-e1076. doi: 10.1016/j.clgc.2018.07.001. Epub 2018 Jul 6.

PMID:
30054221
21.

Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making.

Duvnjak P, Schulman AA, Holtz JN, Huang J, Polascik TJ, Gupta RT.

Urol Clin North Am. 2018 Aug;45(3):455-466. doi: 10.1016/j.ucl.2018.03.010. Review.

PMID:
30031465
22.

Surveillance after prostate focal therapy.

Tay KJ, Amin MB, Ghai S, Jimenez RE, Kench JG, Klotz L, Montironi R, Muto S, Rastinehad AR, Turkbey B, Villers A, Polascik TJ.

World J Urol. 2019 Mar;37(3):397-407. doi: 10.1007/s00345-018-2363-y. Epub 2018 Jun 9. Review.

PMID:
29948045
23.

Predictors of Rectourethral Fistula Formation After Primary Whole-Gland Cryoablation for Prostate Cancer: Results from the Cryo On-Line Database Registry.

Aminsharifi A, Polascik TJ, Schulman A, Tay KJ, Jibara G, Sze C, Tsivian E, Elshafei A, Jones JS.

J Endourol. 2018 Sep 12;32(9):791-796. doi: 10.1089/end.2018.0357. Epub 2018 Jul 31.

PMID:
29943657
24.

Re: Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy with Brachytherapy Boost and Disease Progression and Mortality in Patients with Gleason Score 9-10 Prostate Cancer.

Aminsharifi A, Polascik TJ.

Eur Urol. 2018 Oct;74(4):526. doi: 10.1016/j.eururo.2018.05.031. Epub 2018 Jun 8. No abstract available.

PMID:
29891392
25.

Effect of blood transfusions on oncological outcomes of surgically treated localized renal cell carcinoma.

Tsivian M, Abern MR, Tsivian E, Sze C, Jibara G, Rampersaud EN Jr, Polascik TJ.

Urol Oncol. 2018 Aug;36(8):362.e1-362.e7. doi: 10.1016/j.urolonc.2018.04.014. Epub 2018 May 21.

PMID:
29793797
26.

Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.

Aminsharifi A, Howard L, Wu Y, De Hoedt A, Bailey C, Freedland SJ, Polascik TJ.

J Urol. 2018 Oct;200(4):758-766. doi: 10.1016/j.juro.2018.05.016. Epub 2018 Jul 6.

PMID:
29758219
27.

Focal Therapy for Prostate Cancer: A More Vehement View of the Approach Could Translate into Real Benefits for Our Patients.

Sanchez-Salas R, de la Rosette J, Polascik TJ, Carneiro A, Sivaraman A, Cathelineau X, Walz J.

Eur Urol. 2018 Nov;74(5):537-539. doi: 10.1016/j.eururo.2018.04.018. Epub 2018 May 1.

PMID:
29724502
28.

Defeating Cancers' Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer's Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome.

Baust JM, Rabin Y, Polascik TJ, Santucci KL, Snyder KK, Van Buskirk RG, Baust JG.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818762207. doi: 10.1177/1533033818762207. Review.

29.

Editorial Comment.

Aminsharifi A, Polascik TJ.

J Urol. 2018 Jun;199(6):1508-1509. doi: 10.1016/j.juro.2017.12.078. Epub 2018 Mar 12. No abstract available.

PMID:
29545187
30.

Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative Therapy.

Aminsharifi A, Polascik TJ.

Eur Urol. 2018 Aug;74(2):234-235. doi: 10.1016/j.eururo.2018.01.022. Epub 2018 Feb 7. No abstract available.

PMID:
29428367
31.

Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making.

Duvnjak P, Schulman AA, Holtz JN, Huang J, Polascik TJ, Gupta RT.

Radiol Clin North Am. 2018 Mar;56(2):239-250. doi: 10.1016/j.rcl.2017.10.007. Epub 2017 Dec 11. Review.

PMID:
29420979
32.

Engaging the primary care community to encourage appropriate prostate cancer screening.

Patel MP, Schulman A, Shah KP, Anderson JB, Polascik TJ.

Ther Adv Urol. 2017 Oct 16;10(1):11-16. doi: 10.1177/1756287217735799. eCollection 2018 Jan.

33.

A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men.

Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, Mathur SC, Uchio E, Dong Y, Silberstein JL.

J Urol. 2018 Jun;199(6):1459-1463. doi: 10.1016/j.juro.2017.11.113. Epub 2017 Dec 6.

PMID:
29223389
34.

Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate.

Elshafei A, Tay KJ, Kara O, Malkoc E, Nyame Y, Arora H, Hatem A, Patel SA, Lugnani F, Polascik TJ, Jones JS.

Clin Genitourin Cancer. 2018 Apr;16(2):e477-e482. doi: 10.1016/j.clgc.2017.10.009. Epub 2017 Oct 28.

PMID:
29174470
35.

Most of patients with localized prostate cancer will be treated in the future? | Opinion: No.

Schulman AA, Polascik TJ.

Int Braz J Urol. 2017 Jul-Aug;43(4):584-587. doi: 10.1590/S1677-5538.IBJU.2017.04.03. No abstract available.

36.

New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer?

Holtz JN, Silverman RK, Tay KJ, Browning JT, Huang J, Polascik TJ, Gupta RT.

Abdom Radiol (NY). 2018 Mar;43(3):702-712. doi: 10.1007/s00261-017-1255-8.

PMID:
28721479
37.

Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.

Schulman AA, Howard LE, Tay KJ, Tsivian E, Sze C, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ.

Cancer. 2017 Nov 1;123(21):4122-4129. doi: 10.1002/cncr.30844. Epub 2017 Jun 29.

38.

New advances in focal therapy for early stage prostate cancer.

Tay KJ, Schulman AA, Sze C, Tsivian E, Polascik TJ.

Expert Rev Anticancer Ther. 2017 Aug;17(8):737-743. doi: 10.1080/14737140.2017.1345630. Epub 2017 Jun 28. Review.

PMID:
28635336
39.

The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer.

Schulman AA, Sze C, Tsivian E, Gupta RT, Moul JW, Polascik TJ.

Curr Urol Rep. 2017 Jul;18(7):52. doi: 10.1007/s11934-017-0699-2. Review.

PMID:
28589398
40.

Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance?

Tay KJ, Gupta RT, Holtz J, Silverman RK, Tsivian E, Schulman A, Moul JW, Polascik TJ.

Prostate Cancer Prostatic Dis. 2017 Sep;20(3):323-327. doi: 10.1038/pcan.2017.20. Epub 2017 Apr 25.

PMID:
28440322
41.

Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation.

Nyame YA, Elshafei A, Greene DJ, Arora HC, Given RW, Tay KJ, Polascik TJ, Ross AE, Mouraviev VB, Lugnani F, Jones JS.

J Endourol. 2017 May;31(5):497-501. doi: 10.1089/end.2016.0715.

PMID:
28437170
42.

Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data.

Tay KJ, Polascik TJ, Elshafei A, Tsivian E, Jones JS.

J Endourol. 2017 Jun;31(6):564-571. doi: 10.1089/end.2016.0830.

PMID:
28385075
43.

Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project.

Tay KJ, Scheltema MJ, Ahmed HU, Barret E, Coleman JA, Dominguez-Escrig J, Ghai S, Huang J, Jones JS, Klotz LH, Robertson CN, Sanchez-Salas R, Scionti S, Sivaraman A, de la Rosette J, Polascik TJ.

Prostate Cancer Prostatic Dis. 2017 Sep;20(3):294-299. doi: 10.1038/pcan.2017.8. Epub 2017 Mar 28.

44.

Body mass index and the clinicopathological characteristics of clinically localized renal masses-An international retrospective review.

Tsivian E, Tsivian M, Tay KJ, Longo T, Zukerman Z, Martorana G, Schiavina R, Brunocilla E, Polascik TJ.

Urol Oncol. 2017 Jul;35(7):459.e1-459.e5. doi: 10.1016/j.urolonc.2017.02.004. Epub 2017 Mar 18. Review.

PMID:
28284892
45.

Expanding thermal ablation to the 'intermediate-sized' renal mass: clinical utility in T1b tumors.

Schulman AA, Tay KJ, Polascik TJ.

Transl Androl Urol. 2017 Feb;6(1):127-130. doi: 10.21037/tau.2017.01.08. No abstract available.

46.

High-intensity focused ultrasound for focal therapy: reality or pitfall?

Schulman AA, Tay KJ, Robertson CN, Polascik TJ.

Curr Opin Urol. 2017 Mar;27(2):138-148. doi: 10.1097/MOU.0000000000000372. Review.

PMID:
27997415
47.

Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology.

Tsivian M, Gupta RT, Tsivian E, Qi P, Mendez MH, Abern MR, Tay KJ, Polascik TJ.

Int J Urol. 2017 Feb;24(2):137-143. doi: 10.1111/iju.13251. Epub 2016 Nov 8.

48.

Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project.

Scheltema MJ, Tay KJ, Postema AW, de Bruin DM, Feller J, Futterer JJ, George AK, Gupta RT, Kahmann F, Kastner C, Laguna MP, Natarajan S, Rais-Bahrami S, Rastinehad AR, de Reijke TM, Salomon G, Stone N, van Velthoven R, Villani R, Villers A, Walz J, Polascik TJ, de la Rosette JJMCH.

World J Urol. 2017 May;35(5):695-701. doi: 10.1007/s00345-016-1932-1. Epub 2016 Sep 16.

49.

New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.

Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, Emberton M.

Eur Urol. 2017 Jan;71(1):17-34. doi: 10.1016/j.eururo.2016.08.044. Epub 2016 Aug 29. Review.

PMID:
27595377
50.

Targeted Anterior Gland Focal Therapy-a Novel Treatment Option for a Better Defined Disease.

Tay KJ, Villers A, Polascik TJ.

Curr Urol Rep. 2016 Oct;17(10):69. doi: 10.1007/s11934-016-0628-9. Review.

PMID:
27502428

Supplemental Content

Loading ...
Support Center